Pharmaceuticals, Biotechnology and Life Sciences
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended…
By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response…
Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular…
Zwerling expected to guide the Company to its commercial launchAPOLLO BEACH, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies…
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemias Findings underscore potential…
Two oral presentations showcase robust efficacy and durable responsesBOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) — Imviva Biotech, a clinical-stage biotechnology…
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data…
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies…
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup…